CMOC Group Limited (03993) plans to absorb and merge with Luoyang Smelting.
Connect global capital markets
CMOC Group Limited (03993) announced that Luoyang Luanchuan Molybdenum Industry Group Smelting Co., Ltd. is a wholly-owned subsidiary of the company. In order to further optimize the company's management structure, reduce management costs, and improve operational efficiency, the company plans to absorb and merge Luoyang Smelting through legal procedures.
This merger does not constitute related party transactions, nor does it constitute a major asset restructuring. According to the relevant laws and regulations such as the Company Law of the People's Republic of China and the Company's Articles of Association, this merger needs to be submitted to the company's shareholders' meeting for approval.
This merger is beneficial for further optimizing the management structure, improving operational efficiency, and reducing management costs, in line with the company's development strategy. Luoyang Smelting is a wholly-owned subsidiary of the company, and its business operations mainly come from the company. Its financial statements have been included in the company's consolidated financial statements. This merger is an internal equity consolidation and will not have an impact on the company's financial condition and operating results, nor will it harm the interests of the company and all shareholders.
This merger does not involve changes in the company's name, registered capital, or equity structure, and the composition of the company's board of directors, supervisory board, and senior management remains unchanged.
Related Articles

RNA therapy company Adarx Pharmaceuticals (ADRX.US) plans to raise up to $372 million in a US IPO; pharmaceutical giant AbbVie (ABBV.US) has agreed to invest up to $100 million.

Bank of Canada signals hawkish stance: does not want to act too slowly on rate hikes, oil prices become key risk

US Stock Market Move | Capital Markets Day $23 Billion Target Falls Short of Expectations, Novo Nordisk A/S Sponsored ADR Class B (NVO.US) Drops Over 8%
RNA therapy company Adarx Pharmaceuticals (ADRX.US) plans to raise up to $372 million in a US IPO; pharmaceutical giant AbbVie (ABBV.US) has agreed to invest up to $100 million.

Bank of Canada signals hawkish stance: does not want to act too slowly on rate hikes, oil prices become key risk

US Stock Market Move | Capital Markets Day $23 Billion Target Falls Short of Expectations, Novo Nordisk A/S Sponsored ADR Class B (NVO.US) Drops Over 8%

RECOMMEND





